Symbols / JUNS $0.41 -3.51%
JUNS Chart
About
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation. The company develops JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer's disease. It is also involved in the development of JNS102, which is in Phase II trial for the treatment of mucopolysaccharidosis type 1; and JNS107 that is in Phase II trial for treating mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. In addition, the company develops JNS115, which is in Phase IIa trial for the treatment of Parkinson's disease. It has a strategic partnership with Zina Biopharmaceuticals, LLC to advance Phase 2a clinical trial to evaluate the safety, tolerability, and pharmacokinetics of Resveratrol (JOTROLTM) in individuals with Parkinson's disease; and with Aquanova AG to develop a series of consumer-focused nutritional products targeting longevity, aging, and healthspan. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 14.09M |
| Enterprise Value | 13.55M | Income | -7.60M | Sales | — |
| Book/sh | 0.00 | Cash/sh | 0.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | 6.82 | PEG | — |
| P/S | — | P/B | 204.65 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.29 |
| Current Ratio | 0.65 | Debt/Eq | 314.18 | LT Debt/Eq | — |
| EPS (ttm) | -0.23 | EPS next Y | 0.06 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-14 16:00 | ROA | -3.55% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 34.43M |
| Shs Float | 16.48M | Short Float | 1.13% | Short Ratio | 0.38 |
| Short Interest | — | 52W High | 3.33 | 52W Low | 0.37 |
| Beta | — | Avg Volume | 309.71K | Volume | 406.85K |
| Target Price | $30.00 | Recom | None | Prev Close | $0.42 |
| Price | $0.41 | Change | -3.51% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$30.00
Mean price target
2. Current target
$0.41
Latest analyst target
3. DCF / Fair value
$-1.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.41
Low
$30.00
High
$30.00
Mean
$30.00
- JUNS - JUPITER NEUROSCIENCES, INC. Latest Stock News & Market Updates - Stock Titan Wed, 03 Dec 2025 08
- Is Personalis Inc. stock attractive after correction - Trade Risk Summary & Weekly High Momentum Picks - Naître et grandir Sat, 07 Mar 2026 02
- Parkinson’s trial and Nugevia revenue put Jupiter Neurosciences on BIO stage - Stock Titan Mon, 02 Mar 2026 13
- Jupiter Neurosciences, Inc. Regains Nasdaq Compliance as Stock Price Shows Positive Momentum - Nasdaq hu, 10 Jul 2025 07
- Jupiter Neurosciences Receives Nasdaq Deficiency Notices, Faces Delisting - TipRanks Fri, 27 Feb 2026 08
- Jupiter Neurosciences regains Nasdaq compliance after stock price recovery - Investing.com hu, 10 Jul 2025 07
- Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement - Yahoo Finance hu, 10 Jul 2025 07
- Jupiter Neurosciences Inc. (JUNS) reports earnings - qz.com Fri, 28 Mar 2025 07
- Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing - GlobeNewswire Mon, 27 Oct 2025 07
- Jupiter Neurosciences (NASDAQ: JUNS) wins FDA IND for Phase 2a Parkinson’s trial - Stock Titan Wed, 05 Nov 2025 08
- Jupiter Neurosciences Amends Yorkville Financing Agreement Terms - TipRanks Fri, 20 Feb 2026 08
- Xiaomi founder Lei Jun’s HK$100 million share purchase sparks stock rebound - The Business Times ue, 25 Nov 2025 08
- Jupiter Neurosciences, Inc. (JUNS) - Zacks Investment Research Sat, 15 Jan 2022 12
- Jupiter Neurosciences secures up to $20 million in financing - Investing.com Nigeria Mon, 27 Oct 2025 07
- 2026 stock market outlook - Fidelity Wed, 17 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3600 | 3667.0 | — | Purchase at price 1.01 - 1.02 per share. | ROSEN CHRISTER | Chief Executive Officer | — | 2025-07-01 00:00:00 | D |
| 1 | 750 | 772.0 | — | Purchase at price 1.03 per share. | SILVA ALISON D | President | — | 2025-07-01 00:00:00 | D |
| 2 | 7816 | 7986.0 | — | Purchase at price 0.98 - 1.06 per share. | ROSEN CHRISTER | Chief Executive Officer | — | 2025-06-30 00:00:00 | D |
| 3 | 1800 | 1855.0 | — | Purchase at price 1.00 - 1.05 per share. | SILVA ALISON D | President | — | 2025-06-30 00:00:00 | D |
| 4 | 66293 | nan | — | — | ELMASRI SALEEM C | Chief Financial Officer | — | 2025-06-02 00:00:00 | D |
| 5 | 973466 | nan | — | — | ROSEN CHRISTER | Chief Executive Officer | — | 2025-06-02 00:00:00 | D |
| 6 | 110227 | nan | — | — | SILVA ALISON D | President | — | 2025-06-02 00:00:00 | D |
| 7 | 10781 | 30187.0 | — | Conversion of Exercise of derivative security at price 2.80 per share. | WEIS HOLGER | Director | — | 2025-01-22 00:00:00 | D |
| 8 | 21750 | 60900.0 | — | Conversion of Exercise of derivative security at price 2.80 per share. | BRADY ALLISON W | Director | — | 2025-01-22 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -3.00M | -3.83M | -3.43M | -3.91M |
| TotalUnusualItems | 804.47K | -739.20K | -784.90K | -179.30K |
| TotalUnusualItemsExcludingGoodwill | 804.47K | -739.20K | -784.90K | -179.30K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -2.44M | -4.78M | -4.96M | -4.20M |
| EBITDA | -2.19M | -4.56M | -4.22M | -4.09M |
| EBIT | -2.19M | -4.56M | -4.22M | -4.09M |
| NetInterestIncome | -242.81K | -218.22K | -740.24K | -113.86K |
| InterestExpense | 248.37K | 218.71K | 740.85K | 113.99K |
| InterestIncome | 5.56K | 482.00 | 617.00 | 132.00 |
| NormalizedIncome | -3.24M | -4.04M | -4.17M | -4.02M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -2.44M | -4.78M | -4.96M | -4.20M |
| TotalExpenses | 3.09M | 3.87M | 3.67M | 4.55M |
| TotalOperatingIncomeAsReported | -3.09M | -3.87M | -3.43M | -3.91M |
| DilutedAverageShares | 28.78M | 26.41M | 32.88M | 9.49M |
| BasicAverageShares | 28.78M | 26.41M | 32.88M | 9.49M |
| DilutedEPS | -0.08 | -0.18 | -0.15 | -0.44 |
| BasicEPS | -0.08 | -0.18 | -0.15 | -0.44 |
| DilutedNIAvailtoComStockholders | -2.44M | -4.78M | -4.96M | -4.20M |
| NetIncomeCommonStockholders | -2.44M | -4.78M | -4.96M | -4.20M |
| NetIncome | -2.44M | -4.78M | -4.96M | -4.20M |
| NetIncomeIncludingNoncontrollingInterests | -2.44M | -4.78M | -4.96M | -4.20M |
| NetIncomeContinuousOperations | -2.44M | -4.78M | -4.96M | -4.20M |
| PretaxIncome | -2.44M | -4.78M | -4.96M | -4.20M |
| OtherIncomeExpense | 894.47K | -694.70K | -784.90K | -179.30K |
| OtherNonOperatingIncomeExpenses | 90.00K | 44.50K | ||
| SpecialIncomeCharges | 857.72K | -887.95K | -1.05M | -85.95K |
| OtherSpecialCharges | -857.72K | 887.95K | 1.05M | 85.95K |
| GainOnSaleOfSecurity | -53.26K | 148.75K | 262.51K | -93.35K |
| NetNonOperatingInterestIncomeExpense | -242.81K | -218.22K | -740.24K | -113.86K |
| InterestExpenseNonOperating | 248.37K | 218.71K | 740.85K | 113.99K |
| InterestIncomeNonOperating | 5.56K | 482.00 | 617.00 | 132.00 |
| OperatingIncome | -3.09M | -3.87M | -3.43M | -3.91M |
| OperatingExpense | 3.09M | 3.87M | 3.67M | 4.55M |
| ResearchAndDevelopment | 492.66K | 954.79K | 942.81K | 1.45M |
| SellingGeneralAndAdministration | 2.60M | 2.92M | 2.72M | 3.10M |
| GeneralAndAdministrativeExpense | 2.60M | 2.92M | 2.72M | 3.10M |
| OtherGandA | 2.60M | 2.92M | 2.72M | 3.10M |
| TotalRevenue | 0.00 | 0.00 | 233.28K | 638.04K |
| OperatingRevenue | 0.00 | 0.00 | 233.28K | 638.04K |
| Line Item | 2024-12-31 | 2021-12-31 | ||
|---|---|---|---|---|
| OrdinarySharesNumber | 33.10M | 33.10M | ||
| ShareIssued | 33.10M | 33.10M | ||
| NetDebt | 2.10M | 1.67M | 110.01K | |
| TotalDebt | 217.76K | 2.25M | 1.90M | 651.20K |
| TangibleBookValue | 4.17M | -5.80M | -7.14M | -5.18M |
| InvestedCapital | 4.32M | -3.67M | -5.41M | -4.74M |
| WorkingCapital | 2.64M | -5.74M | -7.19M | -5.23M |
| NetTangibleAssets | 4.17M | -5.80M | -7.14M | -5.18M |
| CapitalLeaseObligations | 71.33K | 119.54K | 165.94K | 210.59K |
| CommonStockEquity | 4.17M | -5.80M | -7.14M | -5.18M |
| TotalCapitalization | 4.17M | -5.69M | -7.14M | -5.18M |
| TotalEquityGrossMinorityInterest | 4.17M | -5.80M | -7.14M | -5.18M |
| StockholdersEquity | 4.17M | -5.80M | -7.14M | -5.18M |
| RetainedEarnings | -26.02M | -23.58M | -18.80M | -13.84M |
| AdditionalPaidInCapital | 30.19M | 17.78M | 11.65M | 8.66M |
| CapitalStock | 3.31K | 2.65K | 2.64K | 653.00 |
| CommonStock | 3.31K | 2.65K | 2.64K | 653.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 2.03M | 5.95M | 7.38M | 5.85M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 21.25K | 178.04K | 119.54K | 164.40K |
| OtherNonCurrentLiabilities | -2.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 21.25K | 178.04K | 119.54K | 164.40K |
| LongTermCapitalLeaseObligation | 21.25K | 71.33K | 119.54K | 164.40K |
| LongTermDebt | 106.71K | |||
| CurrentLiabilities | 2.01M | 5.77M | 7.26M | 5.68M |
| OtherCurrentLiabilities | 1.51M | 710.60K | 351.00K | |
| CurrentDebtAndCapitalLeaseObligation | 196.51K | 2.07M | 1.78M | 486.80K |
| CurrentCapitalLeaseObligation | 50.08K | 48.21K | 46.40K | 46.19K |
| CurrentDebt | 146.43K | 2.02M | 1.73M | 440.61K |
| OtherCurrentBorrowings | 1.64M | 1.64M | 347.13K | |
| CurrentNotesPayable | 146.43K | 383.48K | 93.48K | 93.48K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 1.42M | 1.56M | 4.19M | 4.18M |
| PayablesAndAccruedExpenses | 397.55K | 634.01K | 576.47K | 662.33K |
| CurrentAccruedExpenses | 118.87K | 444.52K | 389.44K | 405.44K |
| InterestPayable | 1.06K | 88.00K | 49.73K | 6.60K |
| Payables | 278.68K | 189.50K | 187.03K | 256.89K |
| AccountsPayable | 278.68K | 189.50K | 187.03K | 256.89K |
| TotalAssets | 6.20M | 148.59K | 235.94K | 667.38K |
| TotalNonCurrentAssets | 1.55M | 119.85K | 166.28K | 212.71K |
| OtherNonCurrentAssets | 3.78K | 3.78K | 3.78K | 3.78K |
| NonCurrentPrepaidAssets | 1.48M | 0.00 | ||
| NetPPE | 69.64K | 116.07K | 162.50K | 208.93K |
| AccumulatedDepreciation | -166.37K | -119.94K | -73.51K | |
| GrossPPE | 236.01K | 236.01K | 236.01K | 208.93K |
| OtherProperties | 208.93K | |||
| BuildingsAndImprovements | 236.01K | 236.01K | 236.01K | |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 4.65M | 28.74K | 69.66K | 454.67K |
| OtherCurrentAssets | 114.09K | 261.00 | 5.23K | 124.07K |
| PrepaidAssets | 766.67K | 0.00 | ||
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 3.77M | 28.48K | 64.43K | 330.60K |
| CashAndCashEquivalents | 3.77M | 28.48K | 64.43K | 330.60K |
| CashFinancial | 3.77M | 28.48K | 64.43K | 330.60K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -3.91M | -480.95K | -1.25M | -1.74M |
| RepaymentOfDebt | -2.36M | 0.00 | 0.00 | |
| IssuanceOfDebt | 138.50K | 390.00K | 982.33K | 527.65K |
| IssuanceOfCapitalStock | 9.88M | 55.00K | 0.00 | 0.00 |
| InterestPaidSupplementalData | 147.78K | 28.13K | 81.50K | 1.06K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 3.77M | 28.48K | 64.43K | 330.60K |
| BeginningCashPosition | 28.48K | 64.43K | 330.60K | 208.00K |
| ChangesInCash | 3.74M | -35.95K | -266.17K | 122.60K |
| FinancingCashFlow | 7.65M | 445.00K | 982.33K | 1.86M |
| CashFlowFromContinuingFinancingActivities | 7.65M | 445.00K | 982.33K | 1.86M |
| NetOtherFinancingCharges | 500.00K | |||
| ProceedsFromStockOptionExercised | 830.00K | |||
| NetCommonStockIssuance | 9.88M | 55.00K | 0.00 | 0.00 |
| CommonStockIssuance | 9.88M | 55.00K | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | -2.22M | 390.00K | 982.33K | 527.65K |
| NetShortTermDebtIssuance | 390.00K | 0.00 | 527.65K | |
| ShortTermDebtPayments | 0.00 | |||
| ShortTermDebtIssuance | 390.00K | 0.00 | 527.65K | |
| NetLongTermDebtIssuance | -2.22M | 390.00K | 982.33K | 0.00 |
| LongTermDebtPayments | -2.36M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 138.50K | 390.00K | 982.33K | |
| OperatingCashFlow | -3.91M | -480.95K | -1.25M | -1.74M |
| CashFlowFromContinuingOperatingActivities | -3.91M | -480.95K | -1.25M | -1.74M |
| ChangeInWorkingCapital | -2.57M | 2.35M | 1.55M | 781.29K |
| ChangeInOtherWorkingCapital | 843.12K | |||
| ChangeInOtherCurrentAssets | -1.78K | 25.00 | 58.12K | -35.44K |
| ChangeInPayablesAndAccruedExpense | -150.11K | 2.34M | 1.49M | 690.49K |
| ChangeInAccruedExpense | -580.00 | 2.18M | 1.55M | 845.75K |
| ChangeInInterestPayable | 46.37K | 38.27K | 43.13K | 2.63K |
| ChangeInPayable | -149.53K | 164.88K | -56.28K | -155.26K |
| ChangeInAccountPayable | -149.53K | 164.88K | -56.28K | -155.26K |
| ChangeInPrepaidAssets | -2.41M | 4.97K | ||
| ChangeInReceivables | 126.23K | |||
| ChangesInAccountReceivables | 126.23K | |||
| OtherNonCashItems | 57.90K | 16.71K | 558.03K | 77.13K |
| StockBasedCompensation | 1.84M | 1.20M | 817.25K | 1.43M |
| OperatingGainsLosses | -804.47K | 739.20K | 784.90K | 179.30K |
| GainLossOnInvestmentSecurities | 53.26K | -148.75K | -262.51K | 93.35K |
| NetIncomeFromContinuingOperations | -2.44M | -4.78M | -4.96M | -4.20M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for JUNS
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|